Alamar Biosciences reports company developments tied to its Precision Proteomics platform, NULISA technology, and commercialization of instruments, consumables, assays, panels, and services for protein biomarker analysis. Recurring updates include financial results, product launches such as NULISAseq and NULISAqpcr offerings, platform adoption among research and biopharma customers, and public-company milestones following its Nasdaq listing.
Company news also covers healthcare conference participation and corporate updates related to the business model for proteomics tools used in disease research and early-detection applications.
Alamar Biosciences (ALMR) announced Emory researchers identified a blood-protein signature that distinguished ALS patients from healthy controls with 98.3% balanced accuracy.
Published in Nature Communications, the study used Alamar’s NULISA technology to develop a 10-protein signature from 632 ALS patients and 160 healthy controls. Independent validation in 144 ALS patients and 37 controls showed 98.3% balanced accuracy versus 89.9% for neurofilament light chain alone, an established marker of nerve-fiber damage. The signature also identified some patients missed by that marker, including patients with relatively little disability. It remains a research finding, not a clinically validated screening or diagnostic test.
Alamar Biosciences (ALMR) will report third-quarter 2026 financial results after market close on November 3, 2026.
Management will host a webcast conference call at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Live audio will be available through the Investors section of www.alamarbio.com, with an archived replay available afterward.
Alamar Biosciences (ALMR) appointed former GRAIL CEO Bob Ragusa to its board of directors and added two executives to its leadership team.
Ragusa brings more than two decades of leadership across genomics, diagnostics and biotech and previously served as chief operations officer of Illumina. John Brottem joined as general counsel after serving as general counsel of Outset Medical and holding senior legal positions at Omnicell. Amelia Merrill joined as chief people officer; her previous roles include Senior Vice President, People at Guardant Health and Vice President, People Operations at Outset Medical.
Alamar Biosciences (ALMR) announced a Lancet Neurology study using its NULISAseq CNS 120 panel to examine responses to lecanemab treatment.
Researchers profiled 2,385 plasma samples from 1,967 participants, including 197 patients treated with lecanemab and untreated comparison groups. Among treated patients, 34 of 130 measured biomarkers changed significantly with the number of infusions, and the changes did not all move in the same direction. Proteins associated with amyloid clearance were largely different from those associated with subsequent cognitive decline. Brain-derived forms of tau accounted for four of the top five proteins that most strongly distinguished treated patients from controls both before treatment and at the last infusion stage.
Alamar Biosciences (Nasdaq: ALMR) announced that its management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The company is scheduled for a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time, with live and archived webcasts available via its investors website.
Alamar Biosciences (Nasdaq: ALMR) reported second quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, driven by 35% instrument growth to $7.8 million, 147% consumable growth to $15.5 million, and 49% services and other growth to $6.2 million.
Gross margin improved to 60% from 53%, while operating expenses rose 89% to $31.2 million, leading to an operating loss of $13.5 million and net loss of $13.2 million. Cash, cash equivalents, short-term investments and restricted cash totaled $256.3 million at June 30, 2026.
The company launched the NULISAseq Neuro 220 Panel with an eMTBR-tau assay, the Immune 340 Panel, and expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. Alamar provided full-year 2026 revenue guidance of $116–$120 million, implying 59% year-over-year growth at the midpoint.
Alamar Biosciences (Nasdaq: ALMR) announced an expanded global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to apply its NULISAseq Neuro 220 multiplex protein panel to an additional 86,000 plasma samples. About 21,000 of these are from a national-scale proteomics initiative begun in mid-July 2026.
This builds on a June 2025 multi-center effort that profiled over 55,000 samples with Alamar’s NULISA technology. The combined dataset is projected for completion in 2027 and is expected to exceed 140,000 samples across multiple geographies and cohorts, linked to clinical and longitudinal outcomes and shared via AD Data Initiative infrastructure.
Alamar Biosciences (Nasdaq: ALMR) launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution for translational research and drug development. The assay measures about 340 immune-related proteins from a single sample, expanding on the earlier NULISAseq Inflammation Panel 250.
According to Alamar Biosciences, the panel’s ultra-sensitive technology detects low-abundance cytokines, chemokines, checkpoint regulators, and cell death markers at fg/mL to sub-pg/mL levels, supporting research in cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging, including “inflammaging.” A Sanofi biomarker lead highlighted its combined breadth and sensitivity for immune landscape profiling.
Alamar Biosciences (Nasdaq: ALMR) announced it will report its second quarter 2026 financial results after market close on Monday, August 10, 2026. Management will host a webcast conference call at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the Investors section of the company website, with an archived replay available.
Alamar Biosciences (Nasdaq: ALMR) announced a national proteomics initiative with leading U.S. research universities to profile about 21,000 plasma samples from 10,000 Alzheimer’s Disease Research Center participants using its NULISAseq™ Neuro 220 panel, including a new eMTBR-Tau assay capturing tau tangle burden and multiple neurodegeneration pathways.
The project, part of the CLARiTI portfolio and supported by philanthropic and data-sharing partners, will generate an open, publicly accessible proteomic dataset linked to NACC IDs, enabling AI-driven multimodal analyses to support biomarker discovery, disease classification, and prediction of neurodegenerative disease progression.